Cargando…

Lysosomes as a Target of Anticancer Therapy

Lysosomes are organelles containing acidic hydrolases that are responsible for lysosomal degradation and the maintenance of cellular homeostasis. They play an important role in autophagy, as well as in various cell death pathways, such as lysosomal and apoptotic death. Various agents, including drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Trybus, Wojciech, Trybus, Ewa, Król, Teodora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916765/
https://www.ncbi.nlm.nih.gov/pubmed/36768500
http://dx.doi.org/10.3390/ijms24032176
_version_ 1784886205462085632
author Trybus, Wojciech
Trybus, Ewa
Król, Teodora
author_facet Trybus, Wojciech
Trybus, Ewa
Król, Teodora
author_sort Trybus, Wojciech
collection PubMed
description Lysosomes are organelles containing acidic hydrolases that are responsible for lysosomal degradation and the maintenance of cellular homeostasis. They play an important role in autophagy, as well as in various cell death pathways, such as lysosomal and apoptotic death. Various agents, including drugs, can induce lysosomal membrane permeability, resulting in the translocation of acidic hydrolases into the cytoplasm, which promotes lysosomal-mediated death. This type of death may be of great importance in anti-cancer therapy, as both cancer cells with disturbed pathways leading to apoptosis and drug-resistant cells can undergo it. Important compounds that damage the lysosomal membrane include lysosomotropic compounds, antihistamines, immunosuppressants, DNA-damaging drugs, chemotherapeutics, photosensitizers and various plant compounds. An interesting approach in the treatment of cancer and the search for ways to overcome the chemoresistance of cancer cells may also be combining lysosomotropic compounds with targeted modulators of autophagy to induce cell death. These compounds may be an alternative in oncological treatment, and lysosomes may become a promising therapeutic target for many diseases, including cancer. Understanding the functional relationships between autophagy and apoptosis and the possibilities of their regulation, both in relation to normal and cancer cells, can be used to develop new and more effective anticancer therapies.
format Online
Article
Text
id pubmed-9916765
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99167652023-02-11 Lysosomes as a Target of Anticancer Therapy Trybus, Wojciech Trybus, Ewa Król, Teodora Int J Mol Sci Review Lysosomes are organelles containing acidic hydrolases that are responsible for lysosomal degradation and the maintenance of cellular homeostasis. They play an important role in autophagy, as well as in various cell death pathways, such as lysosomal and apoptotic death. Various agents, including drugs, can induce lysosomal membrane permeability, resulting in the translocation of acidic hydrolases into the cytoplasm, which promotes lysosomal-mediated death. This type of death may be of great importance in anti-cancer therapy, as both cancer cells with disturbed pathways leading to apoptosis and drug-resistant cells can undergo it. Important compounds that damage the lysosomal membrane include lysosomotropic compounds, antihistamines, immunosuppressants, DNA-damaging drugs, chemotherapeutics, photosensitizers and various plant compounds. An interesting approach in the treatment of cancer and the search for ways to overcome the chemoresistance of cancer cells may also be combining lysosomotropic compounds with targeted modulators of autophagy to induce cell death. These compounds may be an alternative in oncological treatment, and lysosomes may become a promising therapeutic target for many diseases, including cancer. Understanding the functional relationships between autophagy and apoptosis and the possibilities of their regulation, both in relation to normal and cancer cells, can be used to develop new and more effective anticancer therapies. MDPI 2023-01-22 /pmc/articles/PMC9916765/ /pubmed/36768500 http://dx.doi.org/10.3390/ijms24032176 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Trybus, Wojciech
Trybus, Ewa
Król, Teodora
Lysosomes as a Target of Anticancer Therapy
title Lysosomes as a Target of Anticancer Therapy
title_full Lysosomes as a Target of Anticancer Therapy
title_fullStr Lysosomes as a Target of Anticancer Therapy
title_full_unstemmed Lysosomes as a Target of Anticancer Therapy
title_short Lysosomes as a Target of Anticancer Therapy
title_sort lysosomes as a target of anticancer therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916765/
https://www.ncbi.nlm.nih.gov/pubmed/36768500
http://dx.doi.org/10.3390/ijms24032176
work_keys_str_mv AT trybuswojciech lysosomesasatargetofanticancertherapy
AT trybusewa lysosomesasatargetofanticancertherapy
AT krolteodora lysosomesasatargetofanticancertherapy